Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
IPO Year: 2018
Exchange: NASDAQ
Website: unitybiotechnology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/22/2024 | $8.00 | Buy | Rodman & Renshaw |
| 11/16/2023 | $2.00 → $4.00 | Neutral → Outperform | Wedbush |
| 1/4/2022 | $4.00 | Neutral → Buy | Roth Capital |
| 1/4/2022 | Neutral → Buy | ROTH Capital | |
| 11/10/2021 | $5.00 → $7.00 | Neutral → Buy | Mizuho |
| 6/28/2021 | Sell → Buy | Citigroup | |
| 6/28/2021 | $6.00 | Sell → Buy | Citigroup |
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
10-Q - Unity Biotechnology, Inc. (0001463361) (Filer)
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
10-K/A - Unity Biotechnology, Inc. (0001463361) (Filer)
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
144 - Unity Biotechnology, Inc. (0001463361) (Subject)
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
S-8 - Unity Biotechnology, Inc. (0001463361) (Filer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
3 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company's board of directors and as a member of its science committee. "Dr. Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to potentially advance UBX1325 to late-stage development," said Anirvan Ghosh, Ph.
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals. "Dr. Grossi's extensive experience in clinical strategy and a successful track record of advancing novel ophthalmolo
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies. "Alicia's impressive experience in ophthalmology product planning, commercial strategy, and scaling cross-functional teams will be instrumental in fortifying our strategies and capitalizing on the significant opportunity of UBX1325 to transform the treatment landscape for diabetic macular edema (DME)," said Anirvan Ghosh, Ph.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Michael Samar, current chief financial officer at Assembly Bio, has been appointed to the Company's board of directors as its chair of the audit committee and a member of its compensation committee. "We're thrilled to add Michael to UNITY's board of directors. With his strong background in biotech finance and operations, combined with an energetic fresh perspective and track record of execution, Michael's strategic perspective will be vital as we focus on executing on our UBX1325
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has been appointed general counsel. “Alex brings extensive operational and regulatory experience in the life sciences industry that will help him build our company’s legal function,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “He is a dynamic leader with deep roots in the fields of business, government and law. I am pleased to welcome him to our team and believe his expertise will serve us well as we continue to advance our clinic
Rodman & Renshaw initiated coverage of Unity Biotechnology with a rating of Buy and set a new price target of $8.00
Wedbush upgraded Unity Biotechnology from Neutral to Outperform and set a new price target of $4.00 from $2.00 previously
Roth Capital upgraded Unity Biotechnology from Neutral to Buy and set a new price target of $4.00
ROTH Capital upgraded Unity Biotechnology from Neutral to Buy
Mizuho upgraded Unity Biotechnology from Neutral to Buy and set a new price target of $7.00 from $5.00 previously
Citigroup upgraded Unity Biotechnology from Sell to Buy
Citigroup upgraded Unity Biotechnology from Sell to Buy and set a new price target of $6.00
HC Wainwright & Co. initiated coverage of Unity Biotechnology with a rating of Buy and set a new price target of $12.00
Citigroup downgraded Unity Biotechnology from Neutral to Sell and set a new price target of $6.00 from $5.00 previously
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah. ARVO 2025 Presentation Details: Title: Safety and Efficacy of Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b TrialsPresentation Number: 4014 Session: Diabetic Macular Edema: Anti-VEGF Date & Time: Wednesday, May 7,
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, "Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema," the results suggested that the selective clearance of senescent cells in the retina provided disease-modifying and long-lasting improvements in vision in patients with DME, supporting the potential of UBX1325 as a novel
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax) showed vision improvements generally comparable to the aflibercept control, but the study did not meet the primary endpoint of statistical non-inferiority to aflibercept based on BCVA average at weeks 20 and 24. UBX1325 wa
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call with retinal expert Robert B. Bhisi
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here. The event will feature prominent ophthalmology key opinion leader (KOL) Robert Bhisitkul, MD, PhD from the UCSF School of Medicine, who will join company management to review 24- and 36-week results from the Phase 2b ASPIRE study evaluating the safety and efficacy of UBX1325 in patients with DME. UBX1325 is a potent BCL-xL inhibitor that acts via a senolytic mec
SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company's board of directors and as a member of its science committee. "Dr. Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to potentially advance UBX1325 to late-stage development," said Anirvan Ghosh, Ph.
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2024. "We expect to receive 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in this quarter," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "DME remains a significant unmet need, and we believe UBX1325 (foselutoclax) has the potential to provide a differentiated treatment option for patients who continue to experience vision loss despite current standard-of-care
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors (the "Board") granted a stock-based award to a new employee, Federico Grossi, UNITY's Chief Medical Officer, covering options to purchase 150,000 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material indu
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals. "Dr. Grossi's extensive experience in clinical strategy and a successful track record of advancing novel ophthalmolo
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024. "As recently discussed on our Ophthalmology Day for investors and analysts, diabetic macular edema represents a large underserved market due to inadequate response to anti-VEGF standard of care, continued vision loss over time despite treatment, and high treatment burden leading to discontinuation," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "We believe that UBX1325 (foselutoclax) with i
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call with retinal expert Robert B. Bhisi
A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injections through 48 weeks Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the duration of the study UBX1325 had a favorable safety and tolerability profile with no evidence of intraocular inflammation UNITY to host investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., today, April 24 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., April
UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company d
A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment UBX1325 maintained stabilization of retinal structure, as measured by central subfield thickness (CST) at 24 weeks, as compared to worsening from baseline in sham-treated patients The proportion of rescue-free patients in the UBX1325-treated arm was 59.4% at 6 months after a single injection, as compared to only 37.5% in the sham-treated arm UNITY to host investor call with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, today, November 1, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., No
A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham treatment UBX1325 treatment also stabilized retinal structure, as measured by central subfield thickness (CST) at 12- and 18-weeks, as compared to worsening in sham-treated patients The treatment effect was seen in a patient population with visual acuity deficits and residual retinal fluid despite frequent and recent anti-VEGF therapy UNITY to host investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., today, August 12, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 12, 2022 (G
Patients with diabetic macular edema in higher dose cohorts showed a mean BCVA gain of approximately 10 ETDRS letters sustained through 24 weeks after a single intravitreal injection Patients with wet age-related macular degeneration showed improvement in visual acuity through 12 weeks supporting initiation of Phase 2 study in AMD UNITY to host investor call with retinal experts Arshad Khanani, M.D., M.A., and Robert Bhisitkul, M.D., Ph.D., today, November 9, 2021 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, tod
Evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks Sustained responses following single treatment with UBX1325 support durability of senolytic therapeutic approach; data builds on previously reported results at 8 weeks Study remains on track with 24-week data expected before the end of the year UNITY to host investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., on October 5, 2021 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced
UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325 UNITY to host conference call on July 27, 2021, at 8:00 a.m. PT (11:00 a.m. ET) SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a webcast for investors and analysts on July 27, 2021 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss clinical data from the Phase 1 study in diabetic macular ede
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)